TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Solicited Local Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Vaccine-related Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biomarker Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spine goniometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood 4beta-hydroxycholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tinnitus Handicap Inventory (THI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MINI-Tinnitus Questionnaire (Mini-TQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy (sensitivity/specificity) in diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of femoro-tibial osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Insomnia Severity Index- adolescent version (ISI-a)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Medication adherence in glaucoma patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CAARS:Inv
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-ADHD-S
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regional lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression from moderate to severe respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CMV DNA load in inflammatory tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: QF-CMV test result in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AF recurrency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PAC burden total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVC burden total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac symptom burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characteristics of hemodynamically unstable VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adolescent-reported condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Regional Hemoglobin Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 and VCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sexual violence perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in suicidal behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Growth rate of geographic atrophy lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urological injury
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral CCO Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral Hemodynamic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of significant rises in serum antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean serum antibody titers on day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy in CICA aneurysm treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unaided distance visual acuity (UCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unaided intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating and Drinking Ability Classification System (EDACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Endoscopic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of the GlucoMenDay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti Pertussis antibody concentrations pre and post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in magnitude of T-cell responses to pertussis-containing combination vaccines over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Word reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Word reading accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Text reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Text reading accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep retinal capillary vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-PT and Anti-FHA GMTs changed from baseline at 5 Years After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Tetanus and Anti-Diphtheria GMTs changed from baseline at 5 Years After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates for Anti-PT and Anti-FHA Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: severe hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer I Test Without Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Break-up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ultrasound guided ureteroscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Infant psychomotor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Infant bladder and bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity as Defined by NCI CTCAE Version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change from pre-injection pain level at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of advanced colorectal neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sensitivity and specificity of EGFR mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ganglion cell layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to distinguish visual impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Treg Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in degree of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ischemia-reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Image findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-dialysis Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of asymptomatic malaria parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of hospital admissions due to malaria averted
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titer ≥ 1:4 Against Neisseria Meningitidis Serogroup B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma simvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma atorvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma rosuvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic stellate cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seronegative Subjects in Terms of Anti-PT Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Falls and syncope
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Physical Activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Light-Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Moderate and Vigorous-Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peripheral blood gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic and urine pharmacokinetics of MMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective efficacy of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Confirmed Herpes Zoster Cases
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary wedge pressure changes after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Intrathecal Analgesia Following Cesarean Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Pain Scale (0 to 100) at Analgesia Request Following Intrathecal Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen uptake (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Uric Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Rhinoconjunctivitis Symptom Scores (TRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total allergy medication score
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient satisfaction with overall block
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of ReFacto in Hemophilia A subjects undergoing major surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of abnormal genital symptoms and/or pelvic exam findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events and/or abnormal laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Radioactive or Blue Sentinel Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Identification of patients with LV remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in seroma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients receiving metformin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Forced Expiratory Volume first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impulse oscillometry: combined resistance and reactance measures (R5, R20, R5-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of acute GVHD grade II-IV
Endpoint domain: Adverse events/effects
Primary endpoint: isometric muscle strength of arms, legs and trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle function / submaximal performance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the GlowCap system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline nutrient status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mental status evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Composite Asthma Exacerbations (CompEX) Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Delayed Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time of colonic transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in VO2 submax and/or VO2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners' Continuous Performance Test-II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic drop - blood pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average speed of center of pressure oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total area of center of pressure oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiolysis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of joint contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: absence of post-thaw oocyte lysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Major neurodevelopmental impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nausea Complete Response Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Wound Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Noninvasive Tear Breakup Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SASI induration & erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: intima media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nutrition Behavior and Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease-free Survival - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free Survival - Number of Events
Endpoint domain: Mortality/survival
Primary endpoint: Changes in numbers of circulating immune cell population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Capacity to release cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Had CEC Confirmed Composite Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variceal rebleeding
Endpoint domain: Mortality/survival
Primary endpoint: Potassium rate in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline In The PKAN-ADL Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number Of Participants With At Least 1 Treatment-emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Net Procedure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With a Viral Load < 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gain in CD4 Higher Than 100 Cells/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Clinical and Serological Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein staining score (NEI/I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperemia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure from urge urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HAMD)-17 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Trained Users That Performed a Successful Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative mobility of the jaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, relatedness, seriousness and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Nutritional Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of maternal analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-Occurrence RT-PCR Confirmed Influenza A and/or B
Endpoint domain: Mortality/survival
Primary endpoint: non-tumor progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of metabolism biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Food aversion/anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: barrier adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: barrier tack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with cardiovascular/unexplained death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with major bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with coronary or periphery artery disease requiring revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical global impression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recording of extrapyramidal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in manic symptoms over course of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes